BeOne Medicines (ONC) Receivables - Other (2017 - 2023)
BeOne Medicines (ONC) posted quarterly Receivables - Other of $1.7 million for Q4 2023, down 42.91% year-over-year from $3.0 million in Q4 2022, and up 6.57% quarter-over-quarter from $1.6 million in Q3 2023.
BeOne Medicines (ONC) Receivables - Other (2017 - 2023) Analysis & Trends
BeOne Medicines (ONC) has reported Receivables - Other for 7 consecutive years, with $1.7 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Receivables - Other fell 42.91% year-over-year to $1.7 million; the TTM figure through Dec 2023 stood at $1.7 million (down 42.91% YoY), while the FY2023 annual figure was $1.7 million, down 42.91% from the prior year.
- Receivables - Other grew to $1.7 million in Q4 2023 per ONC's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables - Other topped out at $7.2 million in Q3 2021 and bottomed at $1.3 million in Q1 2023.
- Historically, Receivables - Other has averaged $3.8 million across 5 years, with a median of $3.4 million in 2019.
- Annual changes were most pronounced in 2020 — Receivables - Other soared 235.96% — and 2023, when it slumped 74.81%.
- BeOne Medicines' Receivables - Other stood at $1.7 million in 2019, then surged by 283.93% to $6.6 million in 2020, then dropped by 23.67% to $5.1 million in 2021, then tumbled by 39.85% to $3.0 million in 2022, then sank by 42.91% to $1.7 million in 2023.
- Business Quant data shows ONC's Receivables - Other at $1.7 million in Q4 2023, $1.6 million in Q3 2023, and $2.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.74 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Mar 31, 2023 | 1.34 Mn |
| Mar 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 3.04 Mn |
| Dec 31, 2022 | 3.04 Mn |
| Sep 30, 2022 | 2.20 Mn |
| Sep 30, 2022 | 2.20 Mn |
| Jun 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 2.61 Mn |
| Mar 31, 2022 | 5.30 Mn |
| Mar 31, 2022 | 5.30 Mn |
| Dec 31, 2021 | 5.05 Mn |
| Dec 31, 2021 | 5.05 Mn |
| Sep 30, 2021 | 7.22 Mn |
| Sep 30, 2021 | 7.22 Mn |